SUNFISH PARTS 1 AND 2: 4-YEAR EFFICACY AND SAFETY DATA OF RISDIPLAM▼ IN TYPES 2 AND 3 SPINAL MUSCULAR ATROPHY (SMA)
SUNFISH (NCT02908685) is a multicenter, two-part, randomized (2:1, risdiplam▼:placebo), placebo-controlled, double-blind study evaluating the efficacy and safety of risdiplam▼ in patients with Type 2 or Type 3 SMA (inclusion criteria: 2–25 years at enrollment). This presentation will report safety and efficacy data from Parts 1 and 2 of the SUNFISH study after 4 years of treatment with risdiplam▼.
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.